Table 1.
Clinicopathological features and treatment modalities of 98 patients in CQ cohort
| Characteristics | Number (%) |
|---|---|
| Sex | |
| Female | 37 (38%) |
| Male | 61 (62%) |
| Age | |
| <65 | 41 (42%) |
| ≥65 | 57 (58%) |
| Pack-years smoked | |
| <30 | 67 (68%) |
| ≥30 | 31 (32%) |
| Histology | |
| Adenocarcinoma | 88 (90%) |
| Large cell neuroendocrine carcinoma | 1 (1%) |
| Squamous cell carcinoma | 9 (9%) |
| Stage | |
| II | 1 (1%) |
| III | 11 (11%) |
| IV | 86 (88%) |
| T stage | |
| T1/T2 | 40 (41%) |
| T3/T4 | 51 (52%) |
| Tx | 7 (7%) |
| N stage | |
| N0 | 15 (15%) |
| N1 ~ N3 | 80 (82%) |
| Nx | 3 (3%) |
| M stage | |
| M0 | 11 (11%) |
| M1 | 86 (88%) |
| Mx | 1 (1%) |
| Therapy types | |
| Chemotherapy | 18 (18%) |
| Radiation | 6 (6%) |
| Targeted molecular therapy | 34 (35%) |
| Targeted molecular + chemotherapy | 21 (21%) |
| Unknown | 19 (19%) |
| Targeted molecular therapy | |
| A, EGFR-TKI | 1 (1%) |
| EGFR-TKI | 27 (28%) |
| Cri | 1 (1%) |
| A | 5 (5%) |
| Targeted molecular + chemotherapy | |
| Pem, C, EGFR-TKI | 8 (8%) |
| Tax, C, EGFR-TKI | 3 (3%) |
| Tax, C, Pem, EGFR-TKI | 3 (3%) |
| Tax, C, Pem, A | 1 (1%) |
| Pem, C, A | 1 (1%) |
| Tax, C, Cri | 1 (1%) |
| Pem, C, B | 3 (3%) |
| Tax, C, B | 1 (1%) |
| Chemotherapy | |
| C | 1 (1%) |
| Pem | 1 (1%) |
| Pem, C | 5 (5%) |
| Tax, C | 8 (8%) |
| Tax, C, Pem | 3 (4%) |
| Others | |
| Unknown | 25 (26%) |
| TTP status | |
| PD | 55 (56%) |
| PR | 2 (2%) |
| SD | 22 (22%) |
| Unknown | 19 (19%) |
| OS status | |
| Alive | 44 (45%) |
| Dead | 52 (53%) |
| Unknown | 2 (2%) |
Note: Therapeutic drugs used here were anlotinib (A), crizotinib (Cri), gefitinib/erlotinib/icotinib/osimertinib (EGFR-TKI), pemetrexed (Pem), nedaplatin/cisplatin/carboplatin (C), paclitaxel/docetaxel (Tax) and bevacizumab/endostar (B)